MX363367B - Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. - Google Patents

Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.

Info

Publication number
MX363367B
MX363367B MX2015008502A MX2015008502A MX363367B MX 363367 B MX363367 B MX 363367B MX 2015008502 A MX2015008502 A MX 2015008502A MX 2015008502 A MX2015008502 A MX 2015008502A MX 363367 B MX363367 B MX 363367B
Authority
MX
Mexico
Prior art keywords
propyl
diisobutylamino
piperazin
imidazol
benzo
Prior art date
Application number
MX2015008502A
Other languages
English (en)
Spanish (es)
Other versions
MX2015008502A (es
Inventor
Burlet Stéphane
Estrella Cécilia
Barrier Mathieu
Melnyk Patricia
Sergeant Nicolas
Buee Luc
Verwaerde Philippe
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of MX2015008502A publication Critical patent/MX2015008502A/es
Publication of MX363367B publication Critical patent/MX363367B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015008502A 2012-12-27 2013-12-27 Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. MX363367B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
MX2015008502A MX2015008502A (es) 2015-12-16
MX363367B true MX363367B (es) 2019-03-20

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008502A MX363367B (es) 2012-12-27 2013-12-27 Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008333B (zh) 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐,其制备及其用途
JP7500875B2 (ja) * 2020-10-07 2024-06-17 アルツプロテクト 運動ニューロン疾患及び神経筋接合部障害の処置のためのn-(3-(4-(3-(ジイソブチルアミノ)プロピル)ピペラジン-1-イル)プロピル)-1h-ベンゾ[d]イミダゾール-2-アミン硫酸塩及びそれらの溶媒和物の使用
IL313403A (en) * 2021-12-20 2024-08-01 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
ES3075524T3 (en) 2022-03-25 2026-08-05 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも1種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1809288B1 (en) * 2004-11-10 2011-09-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
CN105008333B (zh) * 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途

Also Published As

Publication number Publication date
HUE030930T2 (hu) 2017-06-28
LT2938597T (lt) 2017-01-25
BR112015015474B1 (pt) 2022-04-19
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
PT2938597T (pt) 2016-12-09
NZ708959A (en) 2019-11-29
RS55511B1 (sr) 2017-05-31
HRP20161612T1 (hr) 2017-01-27
AU2018202218A1 (en) 2018-04-26
US10772884B2 (en) 2020-09-15
AU2013369288B2 (en) 2018-02-22
CN105008333B (zh) 2018-02-09
ES2605494T3 (es) 2017-03-14
AU2013369288A1 (en) 2015-07-02
US10537569B2 (en) 2020-01-21
EP2938597B1 (en) 2016-10-26
KR102115060B1 (ko) 2020-05-25
DK2938597T3 (en) 2017-01-09
BR112015015474A2 (enExample) 2017-08-15
US20170151235A1 (en) 2017-06-01
HRP20161612T2 (hr) 2017-02-24
HK1215582A1 (en) 2016-09-02
IL239450A0 (en) 2015-07-30
EP2938597A1 (en) 2015-11-04
RU2655454C2 (ru) 2018-05-29
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
RU2015130671A (ru) 2017-01-30
US20160108003A1 (en) 2016-04-21
CA2895285A1 (en) 2014-07-03
JP2016503813A (ja) 2016-02-08
AU2018202218B2 (en) 2019-02-21
CN105008333A (zh) 2015-10-28
SI2938597T1 (sl) 2017-03-31
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
IL239450B (en) 2018-06-28
KR20150105313A (ko) 2015-09-16
CA2895285C (en) 2021-03-30
JP6384923B2 (ja) 2018-09-05
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
IN2015DN01156A (enExample)
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY157017A (en) Sulfonamide derivatives
NZ708959A (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
MY174188A (en) Heterocyclyl compounds
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2013004307A (es) Derivados de arilamida como bloqueadores de ttx-s.
NZ703731A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MY175854A (en) Novel quinolone derivatives
MX2014012695A (es) Derivados de isoindolona.
MX2012003644A (es) Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila.
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
PH12015501609A1 (en) Phenicol antibacterials
MY160018A (en) 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts
IL216149A (en) Heterocyclic phenoxymethyl compounds, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of central nervous system disorders
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
IN2015DN02109A (enExample)
MX2016016769A (es) Compuestos, composicion farmaceutica y su uso en el tratamiento de enfermedades neurodegenerativas.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
WO2013151719A3 (en) Fluorinated oxazolidinone derivatives
MX2013004650A (es) Polimorfos de febuxostat.
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors